Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, has received approval from the Food and Drug Administration for a new supplemental drug for an opioid analgesic to treat pain related to diabetes.
Nucynta ER is approved to treat neuropathic pain associated with diabetic peripheral neuropathy in adult patients. It is the only opioid approved by the FDA for DPN-associated neuropathic pain.
More Articles on Pain Management:
10 Pain Management Physicians on the Move
ASIPP Releases Guidelines on Opioid Prescriptions for Non-Cancer Pain Patients
Kansas University Hospital Addition Includes Pain Management
Nucynta ER is approved to treat neuropathic pain associated with diabetic peripheral neuropathy in adult patients. It is the only opioid approved by the FDA for DPN-associated neuropathic pain.
More Articles on Pain Management:
10 Pain Management Physicians on the Move
ASIPP Releases Guidelines on Opioid Prescriptions for Non-Cancer Pain Patients
Kansas University Hospital Addition Includes Pain Management